Plasmodium falciparum resistance to most antimalarial compounds has emerged in Southeast Asia and spread to Africa. In this context, the development of new antimalarial drugs is urgent.
High artesunate combination therapy (ACT) treatment failures of Plasmodium falciparum malaria in Southeast Asia has led to triple drug strategies to extend the useful life of ACTs. In this study, we determined whether methylene blue (MB) alters the pharmacokinetics of artesunate-amodiaquine (ASAQ) and enhances the ex vivo antimalarial activity of ASAQ. In an open labelled, randomized cross-over design, a single oral dose of either ASAQ (200 mg AS/540 mg AQ) alone or with MB (325 mg MB) was administered to 15 healthy Vietnamese volunteers. Serial blood samples were collected up to 28 days after dosing.
BASF scientist, Matthias Witschel, is seeking new ways to combat malaria. A 19th century dyestuff is playing an important role.